
Viridian Therapeutics (VRDN) Stock Forecast & Price Target
Viridian Therapeutics (VRDN) Analyst Ratings
Bulls say
Viridian Therapeutics is positioned to be a successful company with its focused product candidates, differentiated approach to treating TED, and promising clinical data for its lead product veligrotug in active and chronic TED. The company's recent FDA approval for Lumvoa and positive early launch metrics indicate a strong potential for revenue growth in the future. With a diverse and inclusive workforce and a sustainable approach to healthcare, VRDN has the potential to achieve peak global sales of $600 million in 2029 and a fair value of $47 per share. However, risks include competition, regulatory hurdles, and the need for additional capital. Overall, our outlook is positive for VRDN given its promising portfolio and strong leadership.
Bears say
Viridian Therapeutics is facing multiple challenges that may negatively affect its stock performance. VRDN-001, its lead asset, is facing significant competition from AMGN's Tepezza, which has already captured a large portion of the thyroid eye disease market. Additionally, VRDN-003, Veligrotug's subcutaneous formulation, may not have a significant advantage over Tepezza, as Tepezza's market resiliency suggests that patient demand for TED treatment remains consistent. These factors, combined with potential regulatory, commercial, and pricing risks, may hinder VRDN's ability to achieve sustained growth and profitability.
This aggregate rating is based on analysts' research of Viridian Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Viridian Therapeutics (VRDN) Analyst Forecast & Price Prediction
Start investing in Viridian Therapeutics (VRDN)
Order type
Buy in
Order amount
Est. shares
0 shares